Thalia Therapeutics

Default features description for sign up page.

Regulatory news

Home

Media

AIM Rule 26

Open Sans

THALIA THERAPEUTICS INVESTOR CENTRE

N4-Pharma-Oncology-programme-initial-pilot-study-2.pdf

N4 Pharma has successfully completed an in vivo confirmatory oncology study which reinforces the results from an earlier pilot study designed to test the ability to use a monodispersed Nuvec® formulation in an intravenous (“i.v”) route of administration using a DNA plasmid (pDNA) encoding TNF alpha, to assess the tolerance of different doses and to look at tumour regression.

N4 Pharma Oncology programme initial pilot study